Brief: Bellicum Receives FDA IND Clearance To Initiate Phase 1/2 Clinical Trial For BPX-603
15/06/2020 13:16
June 15 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* BELLICUM RECEIVES FDA IND CLEARANCE TO INITIATE A PHASE
1/2
CLINICAL TRIAL FOR BPX-603, A DUAL-SWITCH GOCAR-T® FOR HER2+
SOLID TUMORS
* BELLICUM PHARMACEUTICALS INC - TO INITIATE PHASE 1/2
TRIAL WITH
BPX-603 TARGETING SOLID TUMORS THAT EXPRESS HER2 LATER IN 2020
Source text for Eikon: ID:nGNXbKZBt2
Further company coverage: BLCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview